Related Experiment Videos
Microfibrillar collagen hemostat: a new transcatheter embolization agent.
Radiology
|December 1, 1979
Summary
Microfibrillar collagen hemostat (MCH) effectively embolized various vascular lesions in nine patients. While highly thrombogenic and capable of penetrating small arteries, MCH carries a risk of ischemic complications if normal tissues are embolized.
Area of Science:
- Interventional Radiology
- Vascular Surgery
- Oncology
Background:
- Transcatheter embolization is a key treatment for vascular abnormalities and bleeding tumors.
- Developing effective embolic agents that can reach distal vasculature is crucial.
Purpose of the Study:
- To evaluate the efficacy and safety of microfibrillar collagen hemostat (MCH) as an embolic agent.
- To assess MCH's performance in treating diverse vascular lesions and bleeding tumors.
Main Methods:
- Nine patients underwent transcatheter embolization procedures.
- Microfibrillar collagen hemostat (MCH) suspension was used as the embolic agent.
- Procedures included treatment for renal tumors, bladder carcinomas, rectal tumors, esophageal varices, and arteriovenous malformations.
Main Results:
- MCH demonstrated high thrombogenicity and was successfully delivered through small catheters.
- The agent effectively occluded lesions and penetrated small end-arteries.
- Successful embolization was achieved in all nine patients across various pathologies.
Conclusions:
- Microfibrillar collagen hemostat (MCH) is a highly effective embolic agent for transcatheter embolization.
- Its ability to penetrate small vessels makes it suitable for complex lesions.
- Potential risk of ischemic complications necessitates careful embolization technique to avoid normal tissue embolization.